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77 Long-term safety of tobramycin powder for inhalation in patients
with cystic ﬁbrosis: ETOILES study
U. Sommerwerck1, I. Virella-Lowell2, G. Angyalosi3, A.S. Viegas4, A. Iqbal5,
R. Wan4, L. Debonnett4. 1Ruhrlandklinik, West German Lung Center, University
Hospital Essen, Department of Pneumology, Essen, Germany; 2Medical University
of South Carolina, Department of Pediatrics, Pediatric Pulmonology and Sleep
Medicine, Charleston, United States; 3Novartis Pharma AG, DF Critical Care,
Basel, Switzerland; 4Novartis Pharmaceuticals Corporation, East Hanover, United
States; 5Novartis Pharmaceuticals UK Limited, Global Clinical Operations,
Horsham, United Kingdom
Objective: To assess long-term safety (48 weeks) of tobramycin powder for
inhalation (TIP™) by treatment emergent adverse events and supportive efﬁcacy
endpoints in CF patients.
Design: This is a multinational, single-arm, open-label study of 6 cycles of TIP
in CF patients (6 years) with conﬁrmed Pseudomonas aeruginosa (Pa) presence
and a FEV1% predicted 25−75%.
Methods and Baseline characteristics: The study enrolled 157 CF patients
and assessed safety, tolerability, spirometry, change in sputum Pa density and Pa
tobramycin minimum inhibitory concentration. Preliminary baseline demographics
showed over 80% of study population were adults (>18 years) with 62% males.
The mean (±SD) age of patients was 27.8 years (10.82); mean (±SD) BMI was
20.5 kg/m2 (3.35) and mean (range) FEV1% predicted at baseline was 50.1%
(22.5−85.6%). Pre-enrolment medication history (12 months) showed 72% of
patients had exposure to inhaled tobramycin and <6% to other inhaled antibiotics.
Concomitant macrolide use (started at pre-enrollment) was ~18%. The majority of
patients had at least 1 exacerbation in the previous year leading to systemic antibi-
otic treatment and/or hospitalisation. The most frequently used anti-Pa antibiotic
for exacerbations was ciproﬂoxacin (40%).
Conclusion: This long-term safety study has a unique population from prior TIP
studies, predominantly consisting of adult patients with low macrolides use and
more severe airﬂow obstruction. This study complements the long-term data of the
EDIT trials and its two extensions with younger patients (<21 years). Results will
be presented at the congress.
78 Comparison of pierced versus broken capsules on delivered
ﬁne particle dose for the colistimethate dry powder inhaler
M. Ng1, A. Kassamali2, C. Scott1. 1Forest Research Institute, Jersey City, United
States; 2Forest Laboratories UK Ltd, Dartford, United Kingdom
Background: Colistimethate sodium is indicated for the management of chronic
pulmonary infections with P. aeruginosa in patients 6 years of age who have
cystic ﬁbrosis. A 24-week, phase 3 trial has shown that a dry powder inhaler (DPI)
formulation using pierced capsules has better patient acceptability than an earlier
nebulized formulation.
Objectives: To look at possible variations in the delivered dose, we sought to
determine if there is a difference in the ﬁne particle dose and particle size of a
colistimethate capsule that has been previously broken versus pierced by the dry
powder inhaler.
Methods: Capsules were either deliberately broken in the inhaler or pierced by the
inhaler and individually tested using an Andersen Cascade Impactor with high ﬂow
conversion kit (pressure drop of 4 kPa and ﬂow ~70L/min). The ﬁne particle dose
and mass median aerodynamic diameter (MMAD) were determined.
Results: A total of 20 capsules were either broken in (n = 10) or pierced by
(n = 10) the inhaler. Following cascade impaction, the ﬁne particle dose for broken
vs pierced capsules were comparable (range [IU]: 169666–315094 and 181785–
363570, respectively). Additionally, the MMAD was similar between the two
groups, with a range of 4.29–4.66 mm for broken capsules and 4.35–5.21 mm for
pierced capsules.
Conclusion: Results for the ﬁne particle dose and MMAD for broken colistimethate
capsules were consistent with those found for capsules that were pierced by the
inhaler. These results indicate that the delivered dose of colistimethate may not
vary based on whether the capsule has been broken or pierced by the inhaler prior
to inhalation.
79 Intravenous colistin and neurotoxicity: recommendations for
optimal use in cystic ﬁbrosis (CF) patients
P. Schelstraete1,2,3, B. Claus2, S. Snauwaert3, F. Haerynck1, S. Van Daele1,
F. De Baets1. 1Ghent University Hospital, Pediatric Pulmonology and CF Centre,
Ghent, Belgium; 2Ghent University Hospital, Department of Pharmacy, Ghent,
Belgium; 3Ghent University Hospital, Department of Internal Medicine, Ghent,
Belgium
Background: Intravenous (i.v.) colistin is increasingly in CF patients. The most
commonly reported adverse events are neuro- and nephrotoxicity. A protocol for
high dosing of i.v. colistin in adult CF patients (9MIU Colistin methanesulfonate
[CMS] loading dose followed 24 hours later by 2MIU CMS q6h − 30-minute
infusions) evoked two cases of adverse events (paresthesias, bad taste) immediately
after start of infusion.
Objectives: In order to understand the cause of the side effects and to design
additional precautions for colistin use in CF patients, we explored the administration
technique, drug interactions and renal function.
Results: No drug interaction were detected in our patients, renal impairment was
excluded. In literature, doses between approximately 2MIU and 4.5MIU were given
over 9 to 180 minutes and mostly as a 15−60-minute infusion. Toxicity can be
overcome by dose reduction. Only one case report mentioned the inﬂuence of
infusion time on a neurotoxic event. Side effects were overcome by a 1-hour instead
of 30-minute infusion.
We re-adapted the protocol to an infusion rate of 1.5 hours instead of 30 minutes
for the loading dose of 9MIU. There were no further neurotoxic adverse events
since.
Conclusion: Recommendations for optimal administration of i.v. colistin in CF pa-
tients are scarce. As higher doses are used more often, neurotoxicity might become
increasingly important. We recommend to administer the i.v. CMS loading dose of
9MIU over 1.5 hours instead of 30 minutes. For all subsequent doses of 2MIU
q6h we recommend a 30-minute infusion in the absence of toxicity and in case of
neurotoxicity over 1.5 hours.
80 Therapeutical drug monitoring of piperacillin/tazobactam, given as
continuous infusion to patients with cystic ﬁbrosis
K. O¨brink-Hansen1, T.F. Hardlei2, S. Jensen-Fangel1, B. Brock2, M.K. Thomsen3,
E. Petersen1. 1Aarhus University Hospital, Skejby, Department of Infectious
Diseases, Aarhus, Denmark; 2Aarhus University Hospital, Skejby, Department of
Clinical Biochemistry, Aarhus, Denmark; 3Aarhus University Hospital, Skejby,
Department of Clinical Microbiology, Aarhus, Denmark
Objectives: Patients with Cystic Fibrosis (CF) are often colonized with multidrug-
resistant microorganisms, which increases the risk of suboptimal plasma-
concentrations of antibiotics. In pharmacokinetic studies continuous infusion of
beta-lactam antibiotics optimizes the time above the minimum inhibitory con-
centration (T>MIC) compared to intermittent infusion. Continuous infusion with
piperacillin/tazobactam (Pip/Tazo) for a period of 2 weeks has been used at our
department for several years in patients with CF. It is used as an outpatient
treatment and the patients are given 16 g of Pip/Tazo per 24 hours through portable
elastometric infusion pumps. To assess the efﬁcacy and quality of the treatment,
a blood test every 3rd day is obtained to determine the plasma concentration of
Piperacillin, in order to evaluate whether monitoring should be performed as a
routine during treatment or not. The concentration is compared to the MIC for the
bacteria found in a tracheal secretion sample.
Methods: Samples are drawn one hour before changing the infusion bags. Plasma
Piperacillin is quantiﬁed with ultra high performance liquid chromotography.
Results: 4 patients have had their plasma concentration of Pip/Tazo monitored so
far. One patient had a steadily increasing concentration over time whereas the other
three showed an initial increment followed by a decrement. 2 out of 4 patients
maintained a concentration above the MIC.
Conclusion:Monitoring the plasma concentration is helpful in assessing the quality
of outpatient treatment. The decline in concentration with time from starting therapy
might be related to problems with compliance. Further studies in this area are
needed.
